ReBUILD Clinical Trial update

All study visits are complete and data analysis is underway! We are hoping to have results available to the public around April 2016.

The goal of ReBUILD is to to test an already FDA approved medication that has shown promise with remyeliantion.

This investigational drug was approved for the treatment of allergic rhinitis by the Food and Drug Administration (FDA) in past years. Since then, the medication has been identified at UCSF as a compound that potentially enhances remyelination. However, it is not yet approved as a therapy for multiple sclerosis.

If you would like to request more information please contact study coordinator Justin Inman by email at [email protected].